Synapse - Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone Research Letter

Authors:	Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; Tan, C.; Lu, S.; Diamond, B.; Salcedo, M.; Werner, K.; Chung, D. J.; Scordo, M.; Shah, G. L.; Lahoud, O.; Landau, H.; Arcila, M.; Ho, C.; Roshal, M.; Dogan, A.; Derkach, A.; Devlin, S. M.; Giralt, S. A.; Landgren, O.
Title:	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Journal Title:	American Journal of Hematology
Volume:	96
Issue:	6
ISSN:	0361-8609
Publisher:	John Wiley & Sons, Inc.
Date Published:	2021-06-01
Start Page:	E193
End Page:	E196
Language:	English
DOI:	10.1002/ajh.26150
PUBMED:	33661527
PROVIDER:	scopus
PMCID:	PMC8251553
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102720102&doi=10.1002%2fajh.26150&partnerID=40&md5=a796d3426c6ebf1b48a39b153e5da05e
Notes:	Letter -- Export Date: 1 June 2021 -- Source: Scopus